{
    "pmcid": "11461813",
    "qa_pairs": {
        "What is a general consideration for nanobody design against SARS-CoV-2 variants like JN.1 and KP.3?": [
            "Cross-reactivity across multiple variants with convergent mutations",
            "Specificity to a single variant to maximize binding affinity",
            "Targeting only the receptor-binding domain of the spike protein",
            "Focusing solely on the S1 subunit of the spike protein"
        ],
        "What is a key structural change caused by the L455S mutation in the JN.1 variant?": [
            "Increases the number of hydrogen bonds with neighboring residues",
            "Decreases the spike protein's binding affinity to ACE2",
            "Introduces a new disulfide bond in the spike protein",
            "Causes a conformational change that reduces spike protein stability"
        ],
        "What is the implication of the L455S mutation for the design of nanobodies targeting the KP.3 variant?": [
            "Focus on broad-spectrum activity against variants with similar mutations",
            "Design nanobodies to target only the L455S mutation",
            "Avoid targeting the L455S mutation due to its instability",
            "Concentrate on the N-terminal domain of the spike protein"
        ],
        "What mutation in the JN.1 variant enhances spike cleavage and virus entry efficiency in human nasal epithelial cells?": [
            "L455S mutation",
            "D614G mutation",
            "N501Y mutation",
            "E484K mutation"
        ],
        "Which monoclonal antibody shows limited sensitivity to the JN.1 variant?": [
            "S309",
            "REGN10933",
            "Bamlanivimab",
            "Casirivimab"
        ]
    }
}